BD Names Gregory J. Hayes to Board of Directors
Rhea-AI Summary
BD (NYSE: BDX) has appointed Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, currently serves as executive chairman of RTX and brings over 30 years of executive experience. This appointment aligns with BD's transformation strategy, particularly as the company prepares for the planned separation of its Diagnostic Solutions and Biosciences business.
Hayes' extensive background includes CEO and senior leadership roles in finance, corporate strategy, and business development. At United Technologies (UTC), he served as CEO from 2014 and chairman from 2016, playing a key role in the 2020 merger that formed RTX. He previously served as UTC's CFO from 2008 to 2014.
Hayes is the fourth independent director added to BD's board since 2021, demonstrating the company's commitment to board refreshment and strong corporate governance.
Positive
- Planned strategic separation of Diagnostic Solutions and Biosciences business to unlock shareholder value
- Addition of experienced executive with proven track record in portfolio optimization and operational efficiency
- Strengthened board oversight with fourth independent director since 2021
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BDX declined 0.53%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development functions, as well as leadership of large and complex businesses undergoing transformative initiatives, including M&A and spinoff transactions. Hayes' appointment to the BD board of directors is in line with the company's ongoing commitment to strong corporate governance and regular board refreshment. With this appointment, the BD board of directors has added four new, independent directors since 2021.
"Greg will join the board at a pivotal time in BD's transformation, as we seek to unlock significant shareholder value through the planned separation of our Diagnostic Solutions and Biosciences business and launch of the 'New BD' as a medtech leader representing the foundation and future of health care," said Tom Polen, chairman, CEO and president of BD. "Greg's proven track record of portfolio optimization, strategic excellence and driving operational efficiency is well aligned with the BD Excellence operating system and our deep commitment to a culture of continuous improvement. He will be an invaluable asset to our board of directors and the future success of BD."
Prior to his appointment to the RTX board of directors, Hayes' career at United Technologies Corporation (UTC) spanned two decades, culminating in his appointment to chief executive officer in 2014 and chairman in 2016. As CEO, Hayes was instrumental in the formation of RTX — the result of the 2020 merger of UTC's aerospace businesses, Pratt & Whitney and Collins Aerospace, with Raytheon Company. Hayes, who joined UTC in 1999 through its merger with the Sundstrand Corporation, also served as UTC's chief financial officer from 2008 to 2014. He also serves on the board of directors for Phillips 66 Company.
"BD has a remarkable 125-year history as a leading manufacturer of medical devices and is critical to the infrastructure of our health care system," said Hayes. "We have an incredible opportunity ahead, and I look forward to leveraging my experience to help oversee a successful separation and establish 'New BD' as a differentiated and focused pure-play medtech company that is positioned to accelerate innovation, drive profitable growth and deliver long-term sustainable value for all stakeholders."
Hayes earned a bachelor's degree in Economics from Purdue University and is a certified public accountant.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts:
| |
Media: | Investors: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations | Senior Director, Investor Relations |
858.617.2361 | 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-names-gregory-j-hayes-to-board-of-directors-302412390.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What strategic changes is BDX implementing with Hayes' appointment?
How many new independent directors has BDX added since 2021?
What is Gregory Hayes' background before joining BDX's board?
How will the planned separation of BDX's businesses affect shareholders?
